Methods of therapy for chronic lymphocytic leukemia

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 38/20 (2006.01) A61P 35/02 (2006.01)

Patent

CA 2534215

Methods for treating a human with chronic lymphocytic leukemia using a combination of an interleukin-2 and an anti-CD52 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing an IL-2, the other containing an anti-CD2 antibody, according to a dosing regiment. Administering of these two therapeutic agents together results in a positive therapeutic response that is improved with respect to that observed with anti-CD52 antibody alone.

L'invention concerne des méthodes destinées au traitement d'un humain atteint de la leucémie lymphocytaire chronique, consistant à combiner une interleukine-2 avec un anticorps anti-CD52. Ces agents thérapeutiques sont administrés sous forme de deux compositions pharmaceutiques différentes, l'une contenant une IL-2, l'autre un anticorps anti-CD2, selon un schéma posologique précis. L'administration de ces deux agent thérapeutiques ensemble permet d'obtenir une réponse thérapeutique positive qui est meilleure par rapport à celle observée lors de l'utilisation d'un anticorps anti-CD52 seul.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Methods of therapy for chronic lymphocytic leukemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of therapy for chronic lymphocytic leukemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of therapy for chronic lymphocytic leukemia will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1355927

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.